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Brain Its Relevance to the Cardiologist
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CHEUNG, B.M.Y., ET AL.: Brain Natriuretic Peptide: Its Relevance to the Cardiologist. Brain natriuretic peptide, or B-
type natriuretic peptide (BNP), is a cardiac hormone secreted mainly from the ventricles. It is natriuretic, diuretic, vasodilaton/,
loiuers blood pressure and suppresses the renin-angiotensin-aldosterone system. Its concentration in plasma is normally very low
but is markedly raised in congestive heart failure, suggesting that it may have a pathophysiological function. Short-term intravenous
infusion of BNP is beneficial in heart failure but an effective oral agent is not yet available. Plasma BNP concentration may be
measured to assess cardiac function, as it correlates directly with pulmonary capillary wedge pressure and inversely with ejection
fraction.
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Introduction
Brain natriuretic peptide (BNP), was discovered
in 1988 and belongs to a family of natriuretic pep tides
which also includes atrial natriuretic peptide (ANP) and
C-type natriuretic peptide (CNP) (Fig. I).1 Brain
natriuretic peptide is a misnomer, because although it
was first discovered in porcine brain, it is produced
largely by cardiac ventricular muscle and is a circulating
hormone.2 BNP is hardly detectable in the rat or human
brain. Some authors therefore prefer to use the term "B-
type natriuretic peptide".
Structure
In man, the major circulating form of BNP is a
peptide consisting of 32 amino acid residues. The 10th
and the 26th amino acid residues are cysteine. These two
residues link up via a disulphide bond to form a 17-
amino acid loop. This 17-amino acid loop is a structural
motif which is common to the three natriuretic peptides
(Fig. 1). The primary structures (amino acid sequences)
of ANP and CNP are highly conserved amongst
mammalian species. In contrast, the amino acid
sequences of BNP in different mammalian species
diverge considerably.3 Therefore, the homologous
peptide for each species should be studied, and
extrapolation across species should be avoided.
ANP
S-L-R-R-S-S-C-F-G-G-R-M-D-R-I-G-A-Q-S-G-L-G-C-N-S-F-R-Y
I !
BNP
S-P-K-T-M-R-D-S-G-C-F-G-R-R-L-D-R-I-G-S-L-S-G-L-G-C-N-V-L-R-R-y
I I
CNP
G-L-S-K-G-C-F-G-L-K-L-D-R-I-G-S-M-S-G-L-G-C
Figure 1. Amino add sequences of human ANP, BNP and CNP.
Residues common to ail three peptides are indicated by bold type.
Disulphide linkages between two cysteine residues are shown.
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Receptors
BNP binds to the same receptors on the cell surface
membrane as ANP.4 Surprisingly, a receptor which binds
BNP only has not been found. Three subtypes of ANP
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receptors have been identified: ANPR-A, ANPR-B and
ANPR-C (Fig. 2). BNP binds to ANPR-A and ANPR-C.
ANPR-B binds CNP with high affinity, but not ANP or
BNP.
The ANPR-A receptor has intrinsic guanylate
cyclase activity and catalyses the formation of cyclic GMP
(cGMP) when ANP or BNP binds to the receptor. Cyclic
GMP is believed to be the second messenger mediating
the biological actions of the natriuretic peptides.
The ANPR-C receptor is a smaller protein without
the intracellular domain which generates cGMP.
Moreover, it binds not only ANP, BNP and CNP, but also
truncated forms of ANP. It has been suggested that this
receptor has no biological function but serves as a
clearance receptor instead.5
RECEPTOR
ANPR-A
ANPR-B
ANPR-C
LIGAND
ANP, BNP
CNP
ANP, BNP, CNP,
C-ANP, ANP (5-25),
etc.
Figure 2. Known subtypes of ANP receptors and the ligands
which are known to bind to each subtype with high affinity. C-ANP
and ANP(5-25) are synthetic truncated forms of ANP.
Synthesis and Release
The main source of BNP in the circulation is the
heart. BNP messenger RNA (mRNA) is readily
detectable in rat ventricles as well as atria, in contrast to
ANP which is predominantly synthesized and stored in
the atria.6 As the ventricles are larger in mass compared
to the atria, the majority of BNP in the circulation comes
from the ventricles. This has been confirmed in cardiac
catheterisation studies in man which showed that there
was a significant step-up in the plasma BNP level
between the aorta and atrioventricular vein which drains
the ventricles.7
What controls the secretion of BNP is not fully
understood. It is probable that, like ANP, BNP is released
upon stretch of the myocardium. Volume expansion is
associated with increased BNP levels, while
haemodialysis reduces plasma BNP levels.8'9 Although
dietary salt loading increases plasma levels of BNP, acute
intravenous saline loading which would increase plasma
ANP does not increase plasma BNP.10 Similarly, changing
the pacemaker mode from atrial to ventricular pacing
increases ANP much more so than BNP.11 My view is
that ANP is pre-formed and is released acutely in
response to stimulus, whereas BNP is not stored to the
same extent but is synthesised upon stimulation. This
may account for the delay in the BNP response, and is
supported by experiments using isolated perfused rat
hearts, in which BNP mRNA but not ANP mRNA
increased following a rise in atrial pressure, although
there was increased secretion of both peptides.12
Elimination
BNP is eliminated in the circulation by at least two
mechanisms. Firstly, it binds to ANPR-C, the clearance
receptor and is then internalised.5 These clearance
receptors have a widespread distribution and are present
on vascular endothelium. Secondly, BNP is metabolised
by neutral endopeptidase, which cleaves BNP in vitro.a
Inhibiting this enzyme increases plasma BNP levels in
man.14 BNP has a longer half-life in the circulation
compared to ANP.2'15 This may be due to either the lower
affinity of BNP for the clearance receptor,2 or the lower
affinity of BNP as a substrate of neutral endopeptidase.13
Physiological Function
When BNP was originally discovered, it was
shown to have natriuretic, diuretic and hypotensive
effects in the rat.1 In vitro, BNP enhances the production
of cGMP and inhibits aldosterone production in adrenal
cells.16 In laboratory animals, BNP lowers blood
pressure, increases urinary flow rate and sodium
excretion.17 There have been several studies on the effect
of intravenous BNP infusion in man.15'18'21 The earliest
study used porcine BNP and showed suppression of the
renin-angiotensin-aldosterone system and increased
urinary cGMP excretion.18 There was a trend towards
increased urinary sodium excretion, but it should be
noted that porcine BNP differs in sequence from human
BNP. When human BNP was available, several groups
infused BNP in man at different doses using different
protocols.15-19 '21 They all showed that BNP has a
significant natriuretic effect. Studies employing BNP at
supraphysiological doses also showed some hypotensive
effect and suppression of the renin-angiotensin-
aldosterone system.19"21 At a low dose wrhich increases
plasma BNP concentration within the physiological
range, BNP has a significant natriuretic effect without
altering blood pressure and heart rate.15 Moreover, the
effects of ANP and BNP seem to be additive.
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Heart Failure
It was discovered quite early on that plasma BNP
levels are increased markedly in heart failure.22 The
circulating concentration of BNP in normal subjects is in
the low picomolar range, but this is increased by one to
two orders of magnitude in heart failure. The increase is
related to the degree of heart failure. As the effects of
BNP include vasodilation, natriuresis and suppression
of the renin-angiotensin-aldosterone system, BNP has
been postulated to be an endogenous hormone
counteracting the development of heart failure.2 The
administration of ANP to heart failure patients has been
disappointing as the natriuretic effect of ANP seems to
be blunted in such patients. In contrast, BNP, when
infused intravenously in heart failure patients, led to a
marked natriuretic response, accompanied by a decrease
in pulmonary capillary wedge pressure and an increase
in cardiac output.23 BNP, unlike ANP, may therefore be
a useful therapeutic agent in heart failure, but additional
studies are needed to confirm the initial findings of
Yoshimura et al.23 BNP is now available commercially
for intravenous use, but being a peptide, it is both
expensive, unstable and cannot be given orally. A more
rational approach might be the use of oral neutral
endopeptidase inhibitors, such as candoxatril, which can
be used to augment endogenous BNP levels.14 These
agents lower pulmonary capillary wedge pressure, but
it remains to be shown if they are useful clinically in the
long-term treatment of heart failure.24 Heart failure has
a mortality similar to many malignant cancers and
therefore exploring new ways of treating heart failure is
worthwhile. However, several new drugs, e.g. milrinone,
flosequinan, developed for the treatment of heart failure
have been withdrawn because of increased mortality
with treatment. Of concern was the observation that a
drug might improve cardiac function, symptoms and
exercise tolerance of patients but at the same time worsen
survival. Thus therapeutic application of BNP in heart
failure should remain cautious.
Besides heart failure, BNP levels are increased
also in cor pulmonale and renal failure. There is
considerable research interest in the role of BNP in these
conditions.25'26
Hypertension
Until recently, there were no humoral
abnormalities consistently associated with essential
hypertension. Several groups have now described a
significant correlation between blood pressure and
plasma concentrations of natriuretic peptides, including
BNP27-29 The reason for the increase in plasma BNP in
hypertension is as yet uncertain, but it may be related to
ventricular hypertrophy or dysfunction commonly
found in hypertension.
Neutral endopeptidase inhibitors, which augment
endogenous levels of natriuretic peptides, have been
studied in hypertensive patients. There are discrepant
reports on their efficiency in hyper tension,30-3i so further
information on the effects of long-term treatment with
these agents is required to fully assess their therapeutic
potential.
Myocardial Infarction
Plasma level of BNP rises in myocardial infarction
within the first 24 hours, peaking at 21 hours.32 The rise
in BNP is more marked than the rise in ANP/3 and
correlates with peak creatinine kinase and infarct size.32
As BNP is synthesised in the ventricular myocardium, it
is tempting to speculate that BNP is released as a
consequence of myocardial damage. Interestingly, the
BNP level in the acute phase correlates with the ejection
fraction in the convalescent phase, raising the possibility
that measuring the plasma BNP level a f te r acute
myocardial infarction may be of prognostic value.
Furthermore, Motwani and colleagues have followed the
changes in plasma BNP levels and ejection fraction for 6
months after acute myocardial infarction and found a
significant correlation between BNP and ejection fraction
throughout this period.34
Comparison of BNP with the other
Natriuretic Peptides
BNP is different from ANP in a number of ways.
Firstly, analysis of the cDNA of BNP revealed that it
contains the destabilising sequence: "TATTTAT" which
suggests that the turnover of BNP mRNA may be high,
and that it may be synthesised in bursts. Secondly, the
primary structure of BNP in different species is less well-
conserved than those of ANP.3 Thirdly, the storage and
release of the two peptides are different . ANP is
synthesised mainly in the atria and stored as granules.
BNP is synthesised mainly in the ventricles and is not
stored to the same extent. Under stimulation, BNP
mRNA increases acutely, followed by a rise in BNP
secretion. In contrast, stored ANP is released from atrial
granules immediately in response to stimuli. Lastly, BNP
has a longer half-life in plasma which may be due to a
lesser infinity for the clearance receptor.2- > 5
C-type natriuretic peptide (CNP) is the most
recently recognised member of the family of natriuretic
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Figure 3. Correlation between pulmonary arterial BNP
concentrations and pulmonary capillary wedge pressure (r = 0.73, p
< 0.001, n = 30). Reproduced from Haug et al.x with permission of
Clinical Cardiology Publishing Company Inc, and/or the Foundation
for Advances in Medicine and Science Inc, Mahwah, Nj 07430, USA.
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Figure 4. Correlation between plasma BNP concentration and
left ventricular mass index in hypertensive patients. Reproduced
from Kohno et al.2' with permission.
peptides and is distinct from ANP and BNP.35 CNP is
found mainly in the central nervous system, but is also
synthesized and released from endothelial cells and
circulates in plasma.28'36 Vascular smooth muscle cells
express ANPR-B, a guanylate-cyclase coupled receptor
specific for CNP.4 The binding of CNP to this receptor
activates guanylate-cyclase generating cGMP which
mediates vasodilation.37 CNP is also anti-mitogenic and
inhibits the proliferation of vascular smooth muscle
cells.38 Thus, CNP may be an important paracrine factor
in controlling vascular tone and vascular remodelling,
but does not appear to possess the same systemic effects
characteristic of ANP and BNP.
Clinical Importance of BNP
BNP acts in conjunction with ANP and other
fac tors to control sodium excret ion. Thus, in
hypertension, heart failure, renal failure and pre-
edampsia, BNP may play an important pathophy-
siological role. The therapeutic use of BNP in some of
these conditions remains experimental.
As plasma BNP concentration can be measured
readily by radioimmunoassay, there is much recent
interest in the measurement of BNP as an index of cardiac
function. Plasma BNP levels correlate with pulmonary
capillary wedge pressure (Fig. 3)39 and inversely with
ejection fraction.34'40 The plasma level of BNP may
therefore be used as an index of cardiac dysfunction. In
fact, plasma BNP level is as sensitive as echocar-
diography in detecting asymptomatic left ventricular
dysfunction.40 Hence, measurement of BNP may be
useful after myocardial infarction, in deciding whether
or not to introduce an angiotensin converting enzyme
inhibitor,34 or in optimising treatment of heart failure,
especially outside specialised centres where
echocardiography is not readily available. Plasma BNP
levels also correlate strongly with left ventricular mass
in hypertensive patients (Fig. 4).27 This raises the
possibility that plasma BNP might be useful for the
detection of left ventricular hypertrophy, which is
associated with increased cardiovascular morbidity and
mortality in the hypertensive population. Indeed, in
hypertrophic obstructive cardiomyopathy, the plasma
level of BNP is markedly raised, so plasma BNP might
be used, in conjunction with echocardiography, to screen
for this condition.41
Conclusion
BNP is a circulating cardiac hormone which may
be measured to assess cardiac function. A raised
BNP level is a sensitive measure of cardiac dys-
function although not specific for any disease state.
Therapeutic agents which augment the endogenous
levels of ANP and BNP are now being evaluated for
use as therapeutic agents in hypertension and heart
failure.
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